Logotype for Brii Biosciences Limited

Brii Biosciences (2137) investor relations material

Brii Biosciences H1 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Brii Biosciences Limited
H1 2025 earnings summary21 Aug, 2025

Executive summary

  • Advanced core HBV functional cure program with three fully enrolled Phase II-B studies (ENSURE, ENRICH, ENHANCE), targeting viral suppression, immune restoration, and optimal combination regimens for chronic HBV treatment.

  • Out-licensed soralimixin (BRII-693) to Joincare Group for Greater China, focusing resources on HBV and seeking global partners for non-core assets.

  • Maintained a strong cash position, supporting late-stage development and early discovery pipeline through 2028.

  • Strategic partnerships and licensing agreements are expanding the pipeline and addressing antimicrobial resistance.

  • Repurchased 12,723,500 shares for HK$18.2 million, reflecting confidence in business outlook.

Financial highlights

  • Cash and cash equivalents as of June 30, 2025, were RMB2,075.3 million, down 14% from year-end 2024, supporting operations through 2028.

  • Other income for H1 2025 was RMB28.1 million, down 60.4% year-over-year, mainly due to lower interest income and reduced government grants.

  • R&D expenses declined 7.3% year-over-year to RMB117.0 million, reflecting lower third-party and employee costs.

  • Administrative expenses fell 26% year-over-year to RMB58.2 million, driven by organizational optimization and cost control.

  • Loss for the period narrowed 47.5% year-over-year to RMB148.8 million, primarily due to reduced net losses from fair value changes in equity investments and lower operating expenses.

Outlook and guidance

  • 24-week follow-up data from ENSURE Cohort 4 expected in H2 2025; end-of-treatment data from ENRICH and ENHANCE studies anticipated in H1 2026.

  • Unutilized IPO proceeds expected to be fully deployed by end of 2027, mainly for HBV, HIV, and MDR/XDR programs.

  • Focus remains on advancing HBV cure regimens to registrational studies and expanding early discovery pipeline.

  • Ongoing regulatory discussions for phase III trial design, with focus on biomarker-driven patient enrichment and combination regimens.

  • Company remains committed to expanding patient access in China.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Brii Biosciences earnings date

Logotype for Brii Biosciences Limited
H2 202520 Mar, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Brii Biosciences earnings date

Logotype for Brii Biosciences Limited
H2 202520 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Brii Biosciences Limited is a biotechnology company focused on developing therapies for infectious diseases and central nervous system disorders. The company specializes in innovative treatments for conditions such as hepatitis B, HIV, and drug-resistant bacterial infections. It leverages partnerships with global research institutions and biopharmaceutical firms to advance its pipeline through clinical development and regulatory approval. The company is headquartered in Beijing, China, and its shares are listed on the Hong Kong Stock Exchange (HKEX).

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage